Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q1 2019 Earnings Presentation
10 slides from Agilent Technologies's earnings presentation, February 2019
Slide 1: Agilent Technologies Q1'19 Results Presentation
Agilent Technologies Q1’19 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth o
Slide 3: Agilent Results Q1'19
Agilent Results Q1’19 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q1’19 Financial Metrics Q1’19 Headlines • Revenues: $1.28B, +6.1% y/y core(1)(2),+6.0% • Growth: Driven by double-digit growth in reported (+2.1% M&A, -2.2% FX). Pharma, Dx&Clinical, and Envir
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) Instrumentation and Informatics • Core revenue growth moderated relative to +11% for Analytical Laboratories compare. Continued momentum in Pharma, Environmental/Forensics and Cell Analysis. • Operating Margin for the quarter was 26.1%(1)(2), up 20 bps ve
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) Analytical Laboratory Consumables and Services • Continued strong revenue performance across both services and consumables. Balanced growth across regions. • Operating Margin in the quarter was 23.9%(1)(2), up 270 bps versus last year. • Launched new “software as a serv
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) Pathology, Genomics, and • Revenue growth led by demand in NASD, low- Nucleic Acid Manufacturing double digit growth in pathology related businesses and NGS workflow portfolio. • Operating Margin for the quarter was 14.0%(1)(2), up 230 bps versus last year. NGS T
Slide 7: Growth in a $52B Market – Q1'19 Results by End Market
Growth in a $52B Market – Q1'19 Results by End Market Gains highlighted by strong Pharma, Dx&Clinical, and Environmental/Forensics Analytical Laboratory End Markets ▪ Q1'19 revenues: +5% y/y on core(2) basis ▪ Pharma & Biotech: Up 10% with broad-based strength across all segments and regions. Contin
Slide 8: Profitable Growth Plan
Agilent Profitable Growth Plan Recent Actions ▪ Delivering on “Agile Agilent” Initiatives • Multi-year program to increase efficiency and customer focus. • Operating Margin expanded 120 bps in Q1 over prior year(1). ▪ Portfolio Investments and “Go-to-Market” Capability • Launched new “software as a
Slide 9: Strategy to Win
Agilent Strategy to Win Creating shareholder value ▪ Above Market Growth • Innovative, highly differentiated new products and solutions • Win enterprise lab-wide services & consumables - CrossLab • Accelerate bio-pharma penetration • Drive adoption of clinical genomics applications ▪ Aggressively ex
Slide 10: Q2'19 and FY19 Guidance and Forward-looking Considerations
Q2’19 and FY19 Guidance and Forward-looking Considerations Based on January 31, 2019 Exchange Rates Q2’19 Guidance (1) FY Guidance (1) Low End High End Low End High End Net Revenue ($M) $1,255 $1,270 Net Revenue ($M) $5,150 $5,190 Y/Y Core Revenue Growth (2) 5.0% 6.0% Y/Y Core Revenue Growth (2) 5.0